EMA Re-Examines Decisions On Prestige's Trastuzumab And Synchron Studies

Retrieved on: 2022-06-27 15:38:23

Tags for this article:

Click the tags to see associated articles and topics

EMA Re-Examines Decisions On Prestige's Trastuzumab And Synchron Studies. View article details on HISWAI: https://generics.pharmaintelligence.informa.com/GB151985/EMA-Re-Examines-Decisions-On-Prestiges-Trastuzumab-And-Synchron-Studies

Excerpt

Prestige BioPharma's top brass are looking to restore shareholder confidence following the surprise failure of their trastuzumab biosimilar before the ...

Article found on: generics.pharmaintelligence.informa.com

View Original Article